The Molecular Imaging Systems Div. of Eastman Kodak Co. has released a line of imaging agents for use in in vivo applications. The agents are biocompatible and noncytotoxic, making them suitable for research studies in oncology, cardiology, diabetes and inflammatory systems. The agents feature 16- to 17-nm particles and ∼200 activatable attachment sites. Four agents are available, with absorption and emission wavelengths of 549/569, 650/673, 691/715 and 761/789 nm, respectively. According to the company, the agents’ proprietary structures enable increased photostability compared with most other fluorophores.